DDInter1379 DDInter782
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Palbociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Escitalopram
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis A Vaccine
Palbociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sufentanil
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Palbociclib {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Palbociclib may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Sufentanil
Palbociclib may lead to a major life threatening interaction when taken with Amprenavir
Palbociclib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated